Suppr超能文献

产后使用皮质类固醇治疗早产儿慢性肺病:过去、现在与未来

Postnatal corticosteroids in the treatment of chronic lung disease in the preterm infant: past, present, and future.

作者信息

Nye Julie

机构信息

Women & Infants' Hospital, Providence, RI 02905, USA.

出版信息

Neonatal Netw. 2007 Sep-Oct;26(5):293-9. doi: 10.1891/0730-0832.26.5.293.

Abstract

Over the past 20 years, corticosteroid use in the preterm infant has fallen in and out offavor. Steroids were introduced in the 1980s as a mode of preventing and treating chronic lung disease (CLD) in the preterm infant population. This use has been targeted toward low birth weight infants who are unable to wean off the ventilator. Dose, duration, and timing of treatment with dexamerhasone, the steroid typically used in NICUs, has varied. This article examines why the medication has fallen out of favor and whether postnatal corticosteroids still have a place in preventing and treating CLD.

摘要

在过去20年里,早产儿使用皮质类固醇的情况时兴时衰。皮质类固醇于20世纪80年代被引入,作为预防和治疗早产儿慢性肺病(CLD)的一种方式。这种用法针对的是无法撤掉呼吸机的低体重儿。新生儿重症监护病房(NICU)通常使用的类固醇药物地塞米松的剂量、疗程和治疗时机各不相同。本文探讨了这种药物为何失宠,以及产后皮质类固醇在预防和治疗CLD方面是否仍有一席之地。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验